Alto Neuroscience officer proposes $3.6M share sale

The notice ties the proposed shares to stock-option exercises over the next three months.

Rhea-AI Filing Summary

Alto Neuroscience, Inc. (ANRO) is the issuer in officer Nicholas Smith’s notice for a proposed sale of 134,886 common shares, with an aggregate market value of $3,596,060.76. The notice lists September 29, 2026, as the approximate sale date and NYSE as the exchange. Smith states that the shares were and will be received upon exercise of stock options over the next three months; acquisition and payment dates are the exercise/sale dates.

Key Figures

Shares proposed for sale: 134,886 shares Aggregate market value: $3,596,060.76 Approximate sale date: September 29, 2026

3 metrics

Shares proposed for sale 134,886 shares Nicholas Smith’s notice

Aggregate market value $3,596,060.76 Proposed sale

Approximate sale date September 29, 2026 Date listed in the notice

Key Terms

Rule 144, Exercise of Stock Options, NYSE

3 terms

Rule 144 regulatory

"sales required by paragraph (e) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of Stock Options financial

"Exercise of Stock Options"

NYSE market

"NYSE"

A large, regulated marketplace where stocks and other securities are listed and traded, acting like a global auction house that matches buyers and sellers and helps determine share prices. It matters to investors because listing and trading there provide liquidity, price discovery, and regulatory oversight—making it easier to buy or sell holdings and giving companies a visible platform that can affect credibility and access to capital.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ANRO shares did Nicholas Smith plan to sell?

Nicholas Smith’s notice covers a proposed sale of 134,886 common shares, with an aggregate market value of $3,596,060.76. It lists September 29, 2026, as the approximate sale date.

How were the shares in Nicholas Smith’s ANRO notice obtained?

Smith stated that the shares were and will be received upon exercise of stock options over the next three months. The stated acquisition and payment dates are the exercise/sale dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/29/2026 - 04:24 PM Accepted by SEC EDGAR 09/29/2026 - 04:23 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002009130
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ALTO NEUROSCIENCE INC
SEC File Number	001-41944
Address of Issuer	650 Castro Street, Suite 450 Mountain View CALIFORNIA 94041
Phone	6502000412
Name of Person for Whose Account the Securities are To Be Sold	NICHOLAS SMITH
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	134886	3596060.76	39242104	09/29/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/29/2026	Exercise of Stock Options	Issuer			134886	09/29/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Date of Notice	09/29/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/30/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Nicholas Smith
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)